The reasons underlying these discrepant results are unclear and deserve further investigation, though it appears that in a real-world population outside the selective context of a clinical trial, the degree to which GnRH antagonists lower the risk of MACE vs GnRH agonists in men with a history of cardiovascular disease may not be as prominent compared with results observed in the HERO trial. This evidence concerns the gene GNRH1 and cardiovascular disorder.